The MIRD committee, established by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Association of Physicists in Medicine (AAPM), plays a crucial role in standardizing and advancing the field of nuclear medicine by focusing on the dosimetry of internally administered radioactive materials. The primary goal of MIRD is to provide guidelines and recommendations for calculating the absorbed dose to patients from radiopharmaceuticals, which are drugs that contain a radioactive component.
) containing a specific quantity of radioactivity over time. The fundamental MIRD equation is expressed as: MIRD-226
The Medical Internal Radiation Dosimetry (MIRD) Committee has been a leading authority on internal radiation dosimetry for over five decades. The committee's reports and guidelines have provided a framework for calculating and estimating the absorbed dose from internally administered radiopharmaceuticals. MIRD-226 is the latest publication from the committee, offering updated guidelines and recommendations for internal dosimetry. This review aims to provide a comprehensive overview of MIRD-226, highlighting its key concepts, updates, and implications for clinical and research applications. The MIRD committee, established by the Society of
MIRD-226 is a novel, high-affinity radiopharmaceutical designed for the targeted treatment of advanced, metastatic malignancies. The compound combines a highly specific targeting vector (typically a monoclonal antibody or small-molecule peptide) with a potent alpha-emitting radionuclide, such as or Bismuth-212 ( ) . The Mechanism of Action The fundamental MIRD equation is expressed as: The
: Once attached, the tumor cell engulfs the MIRD-226 complex.